GO:0006474 N-terminal protein amino acid acetylation: Protein Stability and Targeting Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006474 describes the acetylation of the N-terminal amino acid of proteins, also called N(alpha)-terminal acetylation.
• N-terminal acetylation is catalyzed by N-terminal acetyltransferases (NATs) that often act co-translationally on nascent polypeptides.
• This modification can shield proteins from degradation and influence protein stability, motility, and longevity.
• N-terminal acetylation creates or destroys degrons recognized by E3 ligases such as CRL2(ZER1/ZYG11B), thereby controlling protein half-life.
• NATs also acetylate histone N-termini, linking N-terminal acetylation to chromatin regulation and cellular stress responses.
• Dysregulation of N-terminal acetylation is implicated in cancer, neurodegeneration, and developmental disorders, making it a target for functional genomics and drug discovery.
Description
N-terminal protein amino acid acetylation (GO:0006474) is a ubiquitous co-translational modification in which an acetyl group is transferred to the alpha-amino group of a protein's first amino acid. This process, also known as N(alpha)-terminal acetylation, is one of the most common protein modifications in eukaryotes and affects a large fraction of the proteome. Unlike lysine acetylation, which typically occurs on internal residues and is reversible, N-terminal acetylation is generally irreversible and occurs on the N-terminal amino acid itself. The modification is catalyzed by a family of N-terminal acetyltransferases (NATs) that recognize distinct N-terminal sequences and act either co-translationally on nascent chains or post-translationally on mature proteins. Researchers study GO:0006474 because it sits at the intersection of protein synthesis, folding, and degradation. N-terminal acetylation can act as a shield against proteasomal degradation, as shown for proteins whose stability depends on the acetylated N-terminus. Conversely, it can create degrons that are recognized by specific E3 ubiquitin ligases, such as CRL2(ZER1/ZYG11B), which target small N-terminal residues for degradation. This dual role makes N-terminal acetylation a critical determinant of protein half-life and a key node in cellular quality control. Beyond protein stability, N-terminal acetylation influences development, aging, and disease. In model organisms, loss of N-terminal acetylation leads to age-dependent motility defects and reduced longevity. NATs also acetylate histone N-termini, contributing to chromatin regulation and gene expression. These findings position GO:0006474 as a central process for understanding proteostasis, aging, and cancer biology.
N-terminal protein amino acid acetylation At A Glance
| GO ID | GO:0006474 |
|---|---|
| GO term | N-terminal protein amino acid acetylation |
| Ontology | biological_process |
| Synonym | N(alpha)-terminal acetylation |
| Definition | The acetylation of the N-terminal amino acid of proteins. |
| Major function | Covalent addition of an acetyl group to the N-terminal amino acid of proteins, influencing protein stability, localization, and interactions. |
| Key enzymes | N-terminal acetyltransferases (NATs) including NatA, NatB, NatC, NatD, NatE, NatF, and NatH. |
| Substrates | Nascent polypeptides and mature proteins with diverse N-terminal sequences. |
| Cellular context | Occurs co-translationally on ribosomes and post-translationally in the cytosol and organelles. |
| Related processes | Protein degradation, protein folding, chromatin regulation, and aging. |
What Is GO:0006474?
GO:0006474, N-terminal protein amino acid acetylation, is defined as the acetylation of the N-terminal amino acid of proteins. In this reaction, an acetyl group is covalently attached to the alpha-amino group of the first amino acid of a polypeptide chain, forming an N-alpha-acetylated protein. The term is synonymous with N(alpha)-terminal acetylation and is classified as a biological process. This modification is distinct from internal lysine acetylation and is typically catalyzed by N-terminal acetyltransferases (NATs) using acetyl-CoA as the acetyl donor.
Why Is N-terminal protein amino acid acetylation Important in Cell Biology?
N-terminal protein amino acid acetylation is important because it is one of the most prevalent protein modifications and directly controls protein stability, interactions, and function. By shielding proteins from degradation or creating degrons, it regulates the half-life of many cellular proteins and impacts processes ranging from motility to longevity. Its dysregulation is linked to cancer, neurodegeneration, and developmental disorders, making it a key area for therapeutic intervention and biomarker discovery.
• N-terminal acetylation is one of the most common protein modifications in eukaryotes, affecting a large fraction of the proteome.
• It can shield proteins from degradation, thereby promoting protein stability and longevity.
• It can create degrons recognized by E3 ligases such as CRL2(ZER1/ZYG11B), targeting proteins for degradation.
• NATs acetylate histone N-termini, linking N-terminal acetylation to chromatin regulation and gene expression.
• Loss of N-terminal acetylation causes age-dependent motility defects and reduced lifespan in model organisms.
• N-terminal acetylation influences protein folding, localization, and interactions, affecting diverse cellular pathways.
• Dysregulation of NATs and N-terminal acetylation is implicated in cancer and neurodegenerative diseases.
• The process is a target for functional genomics and drug discovery, with potential for therapeutic modulation.
• N-terminal acetylation patterns can define protein stability and oxidation states, impacting cellular stress responses.
• Understanding GO:0006474 aids in interpreting proteomics data and designing experiments in cell biology and disease research.
What Happens During N-terminal protein amino acid acetylation?
Recognition of N-terminal sequences by NATs
In simple terms: Enzymes called NATs read the first few amino acids of a new protein to decide whether to add an acetyl group.
N-terminal acetyltransferases (NATs) recognize specific N-terminal sequences of nascent polypeptides. For example, NatA acts on substrates with small residues after the initiator methionine is removed, while NatB and NatC recognize different N-terminal motifs. This sequence specificity ensures that only a subset of proteins is acetylated, contributing to the diversity of N-terminal modifications across the proteome.
Co-translational acetylation on the ribosome
In simple terms: The acetyl group is often added while the protein is still being made on the ribosome.
N-terminal acetylation frequently occurs co-translationally, as the nascent polypeptide emerges from the ribosomal exit tunnel. The NAC (nascent polypeptide-associated complex) guides a ribosomal multienzyme complex that includes NATs and other processing enzymes, ensuring efficient N-terminal modification. This coupling of acetylation to translation allows for rapid processing of newly synthesized proteins.
Acetyl transfer from acetyl-CoA
In simple terms: The NAT enzyme takes an acetyl group from acetyl-CoA and attaches it to the protein's N-terminus.
The catalytic mechanism involves the transfer of an acetyl group from acetyl-CoA to the alpha-amino group of the N-terminal amino acid. Structural and biochemical studies of actin N-terminal acetylation have revealed how NATs bind acetyl-CoA and position the N-terminus for catalysis. This reaction forms a stable amide bond, making N-terminal acetylation largely irreversible.
Post-translational acetylation and quality control
In simple terms: Some proteins are acetylated after they are fully made, and this can affect their stability.
In addition to co-translational acetylation, some proteins undergo post-translational N-terminal acetylation. This can alter protein stability by shielding the N-terminus from recognition by degradation machinery or by creating a degron. For instance, CRL2(ZER1/ZYG11B) recognizes small N-terminal residues, and acetylation can prevent or promote this recognition depending on the context. Thus, N-terminal acetylation serves as a quality control mechanism that influences protein fate.
Histone N-terminal acetylation and chromatin regulation
In simple terms: NATs can also acetylate the tails of histone proteins, affecting how DNA is packaged.
NATs are not limited to cytosolic proteins; they also acetylate histone N-termini. Cellular effects of NAT-mediated histone N-terminal acetylation include changes in chromatin structure and gene expression. This links N-terminal acetylation to epigenetic regulation and cellular stress responses, as histone modifications can be guided by existing marks such as H3K36me3.
Key Genes Involved in GO:0006474 N-terminal protein amino acid acetylation
The following genes encode the major enzymes and regulatory components involved in N-terminal protein amino acid acetylation (GO:0006474).
| Gene | Major Role | Research Relevance |
|---|---|---|
| NAA10 | Catalytic subunit of NatA | Most studied NAT; mutations cause developmental disorders; target for cancer research. |
| NAA15 | Auxiliary subunit of NatA | Regulates NatA activity and substrate specificity; implicated in ribosomopathies. |
| NAA20 | Catalytic subunit of NatB | Acetylates substrates with Met-Glu/Asp N-termini; linked to protein stability. |
| NAA25 | Auxiliary subunit of NatB | Required for NatB function; potential target in neurodegeneration. |
| NAA30 | Catalytic subunit of NatC | Acetylates Met-Ile/Leu/Phe N-termini; involved in aging and motility. |
| NAA35 | Auxiliary subunit of NatC | Modulates NatC activity; studied in longevity models. |
| NAA38 | Auxiliary subunit of NatC | Essential for NatC complex assembly; linked to protein homeostasis. |
| NAA40 | Catalytic subunit of NatD | Acetylates histone H4 and H2A N-termini; role in chromatin regulation. |
| NAA50 | Catalytic subunit of NatE | Acetylates a broad range of substrates; involved in cell cycle and apoptosis. |
| NAA60 | Catalytic subunit of NatF | Golgi-localized NAT; acetylates transmembrane proteins. |
| NAA80 | Catalytic subunit of NatH | Acetylates actin; critical for cytoskeletal dynamics. |
| NAA11 | Testis-specific NAT | Potential role in spermatogenesis and cancer. |
| ZER1 | Substrate receptor of CRL2 E3 ligase | Recognizes non-acetylated N-termini for degradation. |
| ZYG11B | Substrate receptor of CRL2 E3 ligase | Targets small N-terminal residues; interplay with acetylation. |
| NAC (NACA) | Nascent polypeptide-associated complex | Guides NATs to ribosomes for co-translational acetylation. |
| ACTB | Actin, a major NatH substrate | N-terminal acetylation regulates actin polymerization and stability. |
| H3-3A | Histone H3.3 | N-terminal acetylation affects chromatin dynamics. |
| H4C1 | Histone H4 | N-terminal acetylation by NatD influences gene expression. |
How Is N-terminal protein amino acid acetylation Regulated?
N-terminal acetylation is regulated at multiple levels. The expression and activity of NATs are controlled by cellular signals, and the availability of acetyl-CoA can influence acetylation rates. The NAC complex guides NATs to ribosomes, ensuring co-translational modification. Additionally, the interplay between N-terminal acetylation and E3 ligases such as CRL2(ZER1/ZYG11B) provides a regulatory layer for protein degradation. Histone N-terminal acetylation is further modulated by existing chromatin marks, as seen with H3K36me3-guided deacetylation by Rpd3S. These regulatory mechanisms allow cells to adapt N-terminal acetylation patterns to changing conditions, impacting protein stability and gene expression.
N-terminal protein amino acid acetylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NAA10 | Developmental disorders, cancer | Knockout and point-mutation cell lines; patient-derived iPSCs. |
| NAA15 | Ribosomopathy, neurodevelopmental delay | Knockout zebrafish or mouse models; RNA-seq. |
| NAA30 | Age-related motility defects, neurodegeneration | Knockout Drosophila; longevity assays. |
| ZER1/ZYG11B | Cancer, protein degradation disorders | Knockout HEK293 cells; proteomics. |
| NAA80 | Cytoskeletal disorders | Knockout cells; actin polymerization assays. |
N-terminal acetylation in cancer
Dysregulation of N-terminal acetylation is increasingly linked to cancer. NATs such as NAA10 and NAA50 are overexpressed in various tumors and contribute to cell proliferation and survival. The stabilization of oncoproteins by N-terminal acetylation, or the degradation of tumor suppressors due to lack of acetylation, can promote tumorigenesis. Targeting NATs or the degradation machinery that recognizes N-termini, such as CRL2(ZER1/ZYG11B), represents a potential therapeutic strategy.
Neurodegeneration and aging
Loss of N-terminal acetylation leads to age-dependent motility defects and reduced longevity in model organisms. In neurons, impaired N-terminal acetylation may contribute to protein aggregation and neurodegeneration, as acetylation can shield proteins from degradation. The interplay between N-terminal acetylation and oxidative stress, as seen for N-terminal cysteine acetylation and oxidation, further suggests a role in neuronal survival.
Developmental disorders and ribosomopathies
Mutations in NAT subunits, particularly NAA10 and NAA15, cause developmental disorders and ribosomopathies. These conditions highlight the essential role of N-terminal acetylation in translation and protein quality control during development. Understanding how NAT mutations affect substrate acetylation can inform diagnosis and potential therapies.
From N-terminal protein amino acid acetylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NAA10 affect protein stability? | NAA10 knockout cell line (e.g., HAP1) with proteomics. |
| How does N-terminal acetylation of actin regulate polymerization? | NAA80 point-mutation knock-in cells; live imaging. |
| What is the role of NAA30 in aging? | NAA30 knockout mouse or Drosophila; lifespan analysis. |
| Can N-terminal acetylation be used to stabilize a therapeutic protein? | Tagged knock-in of acetylated N-terminus; stability assays. |
| How does CRL2(ZER1/ZYG11B) recognize non-acetylated N-termini? | ZYG11B knockout cells; degron reporter assays. |
| Does histone N-terminal acetylation affect chromatin state? | NAA40 overexpression cells; ChIP-seq. |
How to Study the N-terminal protein amino acid acetylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| N-terminomics | N-terminal peptide sequences and acetylation status | Global profiling of N-terminal acetylation. |
| Ribo-seq | Translation efficiency and ribosome occupancy | Co-translational acetylation studies. |
| CRISPR knockout screens | Gene essentiality and synthetic lethality | Identifying regulators of N-terminal acetylation. |
| Western blot with anti-acetyl antibodies | Specific protein acetylation levels | Validating NAT substrates. |
| Immunoprecipitation-mass spectrometry | Protein-protein interactions | Identifying NAT complexes and substrates. |
| Live-cell imaging | Protein localization and dynamics | Actin acetylation and cytoskeleton studies. |
| ChIP-seq | Histone modification and chromatin state | Histone N-terminal acetylation effects. |
| Lifespan assays | Aging and motility phenotypes | NAA30 knockout models. |
Proteomics for N-terminal acetylation
Mass spectrometry-based proteomics, including N-terminomics, can identify and quantify N-terminal acetylation across the proteome. These methods enable researchers to map NAT substrate specificity and discover how acetylation patterns change in disease models.
Ribosome profiling and Ribo-seq
Ribo-seq measures translation efficiency and can reveal co-translational events such as N-terminal acetylation. By combining Ribo-seq with NAT knockouts, researchers can assess how acetylation affects nascent chain processing and protein output.
CRISPR screens and functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate N-terminal acetylation or its downstream effects. Such screens are useful for uncovering synthetic lethal interactions with NAT mutations and for drug target discovery.
Imaging and biochemical assays
Fluorescence microscopy and biochemical assays can monitor protein stability, localization, and interactions in cells with altered N-terminal acetylation. For example, actin polymerization can be visualized in cells expressing acetylation-deficient actin mutants.
How CRISPR Can Be Used to Study GO:0006474 N-terminal protein amino acid acetylation
Knockout
CRISPR knockout of NAT genes such as NAA10, NAA15, or NAA30 allows researchers to study loss of N-terminal acetylation on protein stability, translation, and cellular phenotypes. Knockout cell lines are valuable for identifying substrates whose acetylation is essential for function.
Point Mutation
Point mutations in NAT catalytic domains or substrate N-termini can dissect the sequence specificity and functional consequences of N-terminal acetylation. For example, mutating the N-terminal residue of actin can prevent its acetylation and reveal its role in polymerization.
Knock-in
Knock-in of tagged or mutant NAT genes enables precise tracking of acetylation events and protein interactions in live cells. Tagged knock-in models can also be used to study the dynamics of NAT complex assembly on ribosomes.
Overexpression
Overexpression of NATs or their substrates can amplify acetylation signals and reveal gain-of-function phenotypes, such as enhanced protein stability or altered chromatin states. This approach is useful for screening small molecules that modulate N-terminal acetylation.
How EDITGENE Supports N-terminal protein amino acid acetylation Research
Researchers studying N-terminal protein amino acid acetylation-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as protein stability, cellular stress resistance, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for N-terminal protein amino acid acetylation research.
Frequently Asked Questions About N-terminal protein amino acid acetylation
What is N-terminal protein amino acid acetylation?
It is the acetylation of the N-terminal amino acid of proteins, also known as N(alpha)-terminal acetylation, catalyzed by NATs.
What genes are involved in N-terminal protein amino acid acetylation?
Key genes include NAA10, NAA15, NAA20, NAA25, NAA30, NAA35, NAA38, NAA40, NAA50, NAA60, and NAA80, which encode NAT subunits.
How does N-terminal acetylation affect protein stability?
It can shield proteins from degradation or create degrons, thereby influencing protein half-life.
What is the role of NAA10 in disease?
NAA10 mutations cause developmental disorders and are linked to cancer through dysregulated acetylation.
Can N-terminal acetylation be targeted for therapy?
Yes, NATs and the degradation machinery recognizing N-termini are potential therapeutic targets in cancer and neurodegeneration.
What methods are used to study N-terminal acetylation?
N-terminomics, Ribo-seq, CRISPR screens, and biochemical assays are commonly used.
What is the difference between N-terminal and lysine acetylation?
N-terminal acetylation occurs on the alpha-amino group of the first amino acid and is largely irreversible, while lysine acetylation is reversible and occurs on internal residues.
Which enzyme acetylates actin?
NAA80 (NatH) acetylates actin, regulating its polymerization and stability.
How does N-terminal acetylation influence aging?
Loss of N-terminal acetylation leads to age-dependent motility defects and reduced longevity in model organisms.
What are the clinical implications of N-terminal acetylation?
Dysregulation is implicated in cancer, neurodegeneration, and developmental disorders, making it a target for diagnostics and therapeutics.
Conclusion
N-terminal protein amino acid acetylation (GO:0006474) is a fundamental co-translational modification that controls protein stability, interactions, and degradation. Its widespread occurrence and impact on aging, cancer, and development make it a critical area of research. Understanding the enzymes, substrates, and regulatory mechanisms of N-terminal acetylation can reveal new therapeutic opportunities and biomarkers. EDITGENE's CRISPR services empower researchers to dissect the causal roles of NATs and related genes, accelerating discoveries in proteostasis and disease biology.
References
- 1. Heathcote KC et al.. 2024. N-terminal cysteine acetylation and oxidation patterns may define protein stability.. Nat Commun 15(1):5360 PMID: 38918375
- 2. Varland S et al.. 2023. N-terminal acetylation shields proteins from degradation and promotes age-dependent motility and longevity.. Nat Commun 14(1):6774 PMID: 37891180
- 3. Lentzsch AM et al.. 2024. NAC guides a ribosomal multienzyme complex for nascent protein processing.. Nature 633(8030):718-724 PMID: 39169182
- 4. Rebowski G et al.. 2020. Mechanism of actin N-terminal acetylation.. Sci Adv 6(15):eaay8793 PMID: 32284999
- 5. Constantinou M et al.. 2023. Cellular effects of NAT-mediated histone N-terminal acetylation.. J Cell Sci 136(7) PMID: 37013828
- 6. van de Kooij B et al.. 2023. N-terminal acetylation can stabilize proteins independent of their ubiquitination.. Sci Rep 13(1):5333 PMID: 37005459
- 7. Li Y et al.. 2022. CRL2(ZER1/ZYG11B) recognizes small N-terminal residues for degradation.. Nat Commun 13(1):7636 PMID: 36496439
- 8. Guan H et al.. 2023. Diverse modes of H3K36me3-guided nucleosomal deacetylation by Rpd3S.. Nature 620(7974):669-675 PMID: 37468628
